QuidelOrtho Corporation (QDEL)

About QuidelOrtho Corporation

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, Japan and Asia Pacific, and Latin America. The company was incorporated in 1979 and is headquartered in San Diego, California.

Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.

Super investor ownership

8 of the funds we track reported a position in their latest SEC 13F filing. Largest first:

• Cliff Asness, AQR CAPITAL MANAGEMENT LLC$15.96M · 0.0% of book
• Israel Englander, MILLENNIUM MANAGEMENT LLC$12.65M · 0.0% of book
• D. E. Shaw, D. E. Shaw & Co., Inc.$4.73M · 0.0% of book
• Mario Gabelli, GAMCO INVESTORS, INC. ET AL$4.40M · 0.0% of book
• Paul Tudor Jones, TUDOR INVESTMENT CORP ET AL$3.41M · 0.0% of book

A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.

Politician trades in QDEL

We hold 9 disclosed trades in QDEL by members of Congress and executive-branch officials. The latest 5:

• Donald J Trump · Executive branchSell · $15,001 - $50,000 · traded 30 Apr 2026 · disclosed 1 Jul 2026
• Donald J Trump · Executive branchSell · $1,001 - $15,000 · traded 29 Jul 2024 · disclosed 22 Sept 2026
• Donald J Trump · Executive branchBuy · $15,001 - $50,000 · traded 4 Jun 2024 · disclosed 22 Aug 2026
• Daniel Goldman · HouseSell · $1,001 - $15,000 · traded 12 Jul 2023 · disclosed 13 Aug 2023
• Gilbert Cisneros · HouseSell · $1,001 - $15,000 · traded 13 Nov 2020 · disclosed 15 Dec 2020

A disclosure reports a value band, not an amount, and is due up to 45 days after the trade; some arrive later. Every filer we track, each with their own page, is on the Congress trading tracker.

Common questions